4 th Annual Clinical Development and Trials Asia Congress. 5 th Annual Pharma R&D World Asia Congress

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "4 th Annual Clinical Development and Trials Asia Congress. 5 th Annual Pharma R&D World Asia Congress"

Transcription

1 Oxford Global Medical Conferences Imaging technologies are proud to present the 4 th Annual Clinical Development and Trials Asia Congress and Implementing biomarkers in co-located early phase Pharma clinical trials R&D Asia Congress to be held on the 27 th Development & 28 th January of Companion 2015 in Shanghai, Diagnostics China. Clinical Attended Trials by over 170 industry leaders in Clinical Development & Clinical Trials Development Managing in Safety Asia, and the Efficacy 4 th Annual Clinical Development and Trials Asia Congress will offer invaluable insights on successful strategies and technologies in enabling clinical development, clinical outsourcing strategies and clinical trial management. On day one hear from senior VPS and Directors in discussing clinical development strategies as well as clinical development in oncology and other therapeutic areas in China, Japan, South Korea, India, & Singapore. It will also cover key discussion on the changing regulatory environment in China and impact of this on multinational drug development activities. Do not miss out on updates in registration for multinational clinical trials and international regulatory updates including FDA breakthrough regulation, EMA RMP regulation There is also a featured enabling technologies stream dedicated to managing Clinical Development, implementing Biomarkers into Drug & clinical research, translational science and Clinical Data Management. Day two will focus on Clinical Trial Management strategies for minimising costs, bridging studies in Asia for Global Development, Safety and Pharmacovigilance and risk management. The 4 th Annual Pharma R&D World Asia congress will discuss novel scientific innovations in Discovery and Development in Asia. Topics will cover: global collaboration, changes in the model of CRO outsourcing & partnering strategies, regulation policies and drug innovation strategies. Our esteemed experts will discuss strategies to accelerate drug development timelines. 4 th Annual Clinical Development and Trials Asia Congress Day 1 Clinical Development Activities & Clinical Outsourcing Strategies Regional clinical development activities in Asia and Asia Pacific regions - China, Japan, South Korea & Singapore Clinical development activities in oncology and other therapeutic areas Selecting the correct Pharma CRO partnership for maximum success Changing regulatory environment in China and impact of this on multinational drug development activities Regulatory updates for Registration for Multinational Clinical Trials China, Japan, South Korea & Singapore Day 1 - Featured Technology Stream Enabling Technologies for Drug Development and Personalised Medicine Imaging biomarkers: bridging preclinical and clinical research Medical Imaging technologies Implementing biomarkers in early phase clinical trials Development of Companion Diagnostics in Clinical Trials Biometrics in Asia Pacific Clinical Trials Clinical Data Management Day 2 Clinical Trials Management Strategies in Asia and Asia Pacific Regions Implementing successful patient recruitment and retention strategies Opportunities of bridging studies in Asia for Global Development Country and site selection for global clinical trials Managing clinical trials in oncology and other therapeutic areas Ensuring pharmacovigilance and patient safety in clinical trials in Asia Managing Safety and Efficacy VP and Director Panel Discussion Topics PANEL 1: Will Asia Produce in Regards to Drug Development PANEL 2: Regulatory updates for Registration for Multinational Clinical Trials China, Japan, South Korea & Singapore PANEL 3: Innovation Strategies to Advance R&D in Asia PANEL 4: CRO - R&D Collaborations and Business Models 5 th Annual Pharma R&D World Asia Congress Day 1 - Innovation Strategies to Advance R&D in Asia R&D collaborations between East & West Guaranteeing successful outsourcing partnerships Successful business models in CRO partnership Multi-national pharma companies in emerging markets International regulatory updates including FDA breakthrough regulation, EMA RMP regulation Targeted Therapy & Molecular Targeted Drugs Drug development in oncology and other therapeutic areas Novel methods to accelerate drug development pipeline In licensing strategies

2 Clinical Asia and R&D Asia Confirmed Speakers 2015: Zhengqing Li, VP and Head of China Development MSD Cezary Statuch, Vice President of R&D, Bristol-Myers Squibb, China Dan Paulson, Vice President, Global Clinical Development, Group Head, Cardiovascular Risk Management and Women s HealthCare, Bayer HealthCare Company Limited Global R&D Centre Oliver Kong, Senior Director, Clinical Development Oncology, Celgene Corporation Akhilesh Sharma, Senior Vice President & Global Head Global Medical Affairs, Dr. Reddy's Laboratories India Victoria Elegant, Vice President of Medical & Regulatory Affairs, Baxter, China Dejun Tang, Site Head, Biometrics & Statistical Sciences and Methodology. Novartis, China Wei Wang, Associate Director, Safety Surveillance and Risk Management, Pfizer, China Yong-jiang Hei, Executive Medical Director, Amgen China Jagdev Sidhu, Senior Director Clinical Pharmacology & Pharmacometrics,CSL Limited Patrecia Valone, Senior Director, Development Operations, Takeda Development Center Asia and Takeda Shanghai Development Center Hua Mu, Senior Vice President, Global Head of Product Development Service and Partnership Business Unit, WuXi AppTec (Shanghai) Co., Ltd Jessie Gu, Head, Translational Medicine China, Novartis Institute for Biomedical Research, China Ming Ji, Sr. Medical Director, Medical Safety Evaluation, AbbVie Jason Yang, Senior Vice President, Head of Clinical Development, BeiGene(Beijing)Co., Ltd Yingmei Tu, Clinical Research Director, Merck Ralf Altmeyer, Director General, Institut Pasteur Shanghai, Chinese Academy of Sciences Yan Wu, Executive Director, Head of Clinical Operations and Drug Safety, Hutchison Medi Pharma Jennifer Huang Executive Director, Head of Global Clinical Trial Operations, Merck Research Laboratories R&D (China) Ltd Jingsong Wang, Head of China R&D, Head of Translational Medicine, Asia Pacific, Sanofi Chih-Liang Chin, Director and Site Lead, Imaging, Merck Singapore Frank Grams, VP, Head Alliance Management & Transactions, Sanofi R&D David Tattersall, Director, Neurodegeneration Parkinson's Disease Group, GSK R&D China Shanghai Mingde Xia, Senior Director, Johnson & Johnson Innovation Center, Asia Pacific Jenny Wei, Head of R&D Information Asia & EM, Innovation Center China, AstraZeneca Global R&D Zheng Li, General Manager, Head of Research China, Lundbeck Jun Bao, Senior Vice President and Chief Business Officer, Shenogen Pharma Group Jian Li, Director, Partnering and External Innovation - Asia Pacific, Sanofi R&D Yariv Hefez, Vice President Business Development, Portfolio Management, Strategy and Partnering, Biosimilars Unit, Merck Zhenping Wu, Senior Vice President, Pharmaceutical Sciences, Hutchison Medi Pharma Ming Guo, Co-Founder & COO, Ascentage Pharma Amar Kureishi, Chief Medical Officer and Head of Drug Development, Quintiles Asia Event Sponsor:

3 Hear from our 2015 Speakers: Cezary Statuch BMS Zhengqing Li MSD Yong Hei Amgen David Tattersall GSK Jingsong Wang Sanofi Patrecia Valone Takeda Jagdev Sidhu CSL Akhilesh Sharma Dr Reddy s Lab Who You Will Meet 175 senior attendees from leading academic institutions, pharmaceutical organisations and biotechnology companies will be attending. Meet VPs, Directors & Senior Managers with the following job titles: Clinical Research Clinical Biomarkers Clinical Supply Chain Safety In licensing Clinical Outsourcing Clinical Trial Management Personalised Medicine Regulatory Affairs Business Development Clinical Operations Clinical Development Translational Medicine Preclinical Development Biomarkers Patient Safety Medical Affairs Research and Development Discovery Data Management Networking And Business Meeting Opportunities Meet face-to-face with leading solution providers and senior-level industry peers through a series of formal and informal networking opportunities. Categories of solution provider include: Clinical Testing Supply Chain Management Cold Chain Management PKPD Clinical Trial Design Regulatory Compliance Outsourcing Strategies Imaging Solutions & Management Translational Research Companion Diagnostics Discovery Solutions Assay Development Patient Selection Biomarker solutions Data Management Biometric

4 4 th Annual Clinical Asia Congress & 5 th Annual Pharma R&D Asia Congress Day One 27 th January Registration: The Atrium Conference Room: New Asia Ballroom 1 - Oxford Global s Welcome Address Chairperson s Opening Address Directors and VPs Panel Discussions Directors and VPs Panel Discussion Will Asia Produce in Regards to Drug Development Drug development in Asia is undergoing significant changes these days (regulatory, clinical, operational, etc.) and many companies are now experiencing a gap in terms of seeing results from significant investment in the region. Investments in infrastructure and development programs in Asia (sites and patients) have been made. The panel will discuss challenges in the productivity of sites, quality of production, and the changing regulatory environment in China, and will also rethink Development strategies for Multinationals.. Confirmed Panel Moderator: Dan Paulson, Vice President, Global Clinical Development, Group Head, Cardiovascular Risk Management and Women s HealthCare, Bayer HealthCare Company Limited Global R&D Centre Confirmed Panel: Cezary Statuch, Vice President of R&D, Bristol-Myers Squibb, China Akhilesh Sharma, Senior Vice President & Global Head Global Medical Affairs, Dr. Reddy's Laboratories India Yong-jiang Hei, Executive Medical Director, Amgen China Zhengqing Li, VP and Head of China Development, MSD Directors and VPs Panel Discussion Changing Regulatory Environment in China and Impact of this on Multinational Drug Development Activities Confirmed Panel Moderator: Cezary Statuch, Vice President of R&D, Bristol-Myers Squibb, China Confirmed Panel: Victoria Elegant, Vice President of Medical & Regulatory Affairs, Baxter, China Michael Rozycki, Vice President, Regulatory Affairs Asia Pacific, Allergan (TBA) Ming Guo, Co-Founder & COO, Ascentage Pharma Innovation Strategies to Advance R&D in China and Asia Open Innovation / Collaboration Strategy (east-west, academia-industry, company-company, private-public, incubator, consortium, co-investment, etc). Collaboration models (PPP, risk sharing) Innovation Strategies to boost China as a global R&D center Successful business models in Pharma R&D The role of MNC vs local companies in developing China as a Global R&D source What does the future hold, China in 2024 Panel Moderator: Jingsong Wang, Head of China R&D, Head of Translational Medicine, Asia Pacific, Sanofi Confirmed Panel: Mingde Xia, Senior Director, Johnson & Johnson Innovation Center, Asia Pacific Zheng Li, General Manager, Head of Research China, Lundbeck Jian Li, Director, Partnering and External Innovation - Asia Pacific, Sanofi R&D Yariv Hefez, Vice President Business Development, Portfolio Management, Strategy and Partnering, Biosimilars Unit, Merck Jun Bao, Senior Vice President and Chief Business Officer, Shenogen Pharma Group Directors and VPs Panel Discussion R&D Collaborations - The Changing Nature of CRO and Sponsor Relationships Type of R&D collaboration how the CRO is changing their model of support for domestic local clients and multinational clients Are the collaboration/business models different for China based clients versus that of other regions Training and dealing with workforce to sustain success in collaborations

5 CRO - innovative models of service offerings Selecting the Right Pharma CRO partnership for Maximum Success Confirmed Panel: Frank Grams, VP, Head Alliance Management & Transactions, Sanofi R&D David Tattersall, Director, Neurodegeneration Parkinson's Disease Group, GSK R&D China Shanghai Solution Provider Presentation For enquiries, please Exhibition Room: The Atrium Morning Coffee & Refreshments One to One Meetings x3 R&D Asia Congress Innovation Strategies to Advance R&D in Asia Clinical Asia Congress Clinical Development Activities & Clinical Research Outsourcing Strategies Enabling Technologies for Drug Development and Translational Medicine Conference Room: New Asia Ballroom 1 Conference Room: New Asia Ballroom 2 Conference Room 3: Stream Chair: Stream Chair: Stream Chair: New Drug Development, Global Health Trends and the Future of Bio-Pharma in Asia CONFIRMED: Amar Kureishi, Chief Medical Officer and Head of Drug Development, Quintiles Asia Solution Provider Presentation Global vs Local: Clinical Development, Clinical Trials & CRO Selection CONFIRMED: Yan Wu, Executive Director, Head of Clinical Operations and Drug Safety, Hutchison Medi Pharma Biomarkers in Early Clinical Development The key focus on early clinical development is achieve go vs. no go decision, early readout of intended pharmacological activities is critical. Well mapped biomarker strategy is must to have to achieve such goal. In addition of assessing pharmacological or intended biological activities, biomarker has been used routinely for patient selection and stratification. Validating and implementing biomarker strategy are essential for effective early development CONFIRMED: Zaiqi Wang, Head of Clinical Research, Merck, China Exhibition Room: The Atrium Lunch Hutchison Medi Pharma s Drug Development Pipeline and Innovation in China and other regions of Asia CONFIRMED: Zhenping Wu, Senior Vice President, Pharmaceutical Sciences, Hutchison Medi Pharma Regional Clinical Development in Asia and Asia Pacific Regions CONFIRMED: Yingmei Tu, Clinical Research Director, Merck Biomarker Development In Clinical Trials Design in Oncology CONFIRMED: Oliver Kong, Senior Director, Clinical Development Oncology, Celgene Corporation

6 Innovative Collaboration In Pharmaceutical R&D - managing our global network of alliances CONFIRMED: Frank Grams, VP, Head Alliance Management & Transactions Sanofi R&D Exploring and Applying Innovative Strategies and Models to Pursue Effective New Drug Development in China CONFIRMED: Hua Mu, Senior Vice President Global Head of Product Development Service and Partnership Business Unit, WuXi AppTec (Shanghai) Co., Ltd Implementing Biomarkers in Clinical Development in China CONFIRMED Jessie Gu, Head, Translational Medicine China, Novartis Institute for Biomedical Research, China Conference Room: New Asia Ballroom 1 Conference Room 2: New Asia Ballroom 2 Conference Room Drug Development in Asia - Regulatory Strategies and Clinical Plan Key Developments in Regional and Global Clinical Trial Activities & Clinical Research Outsourcing Strategies Regulatory Requirements Clinical plans for Global Clinical Studies CONFIRMED: Jason Yang, Senior Vice President, Head of Clinical Challenges and Opportunities CONFIRMED: Ralf Altmeyer, Director Development, BeiGene(Beijing) Co., Ltd General, Institut Pasteur Shanghai, Chinese Academy of Sciences Exhibition Room: The Atrium Afternoon Refreshments One to One Meetings x Development of Translational Imaging Biomarker for Drug Discovery and Development Leverage advanced imaging technologies to understand disease biology and validate novel therapeutic targets Develop biomarkers using multi-modality imaging approaches across species to de-risk clinical development Enable early GO/No-Go decisions using translational imaging biomarkers in animal models of human disease and humans. CONFIRMED: Chih-Liang Chin, Director and Site Lead, Imaging, Merck Singapore Cardiovascular Drug Development: Cardiogenomics and Asia, is there Potential for a Personalized Approach to Medical Care? CONFIRMED: Dan Paulson, Vice President, Global Clinical Development, Group Head, Cardiovascular Risk Management and Women s HealthCare, Bayer HealthCare Company Limited Global R&D Centre Companion Diagnostics Development in Both Preclinical and Clinical Context Tero Laulajainen, RPD Global Head of Clinical Operations, Roche Diagnostics International Ltd, Switzerland Biometrical Challenges in Asia Pacific Clinical Trials Current status of biometrics applications in clinical trials including Asia Quantitative trial design and decision making Challenges due to new innovations and health authority requirements Difference in challenges for global pharma and domestic ones Impact from big data and its applications CONFIRMED: Dejun Tang, Head of Integrated Information Sciences, Site Head, Biometrics & Statistical Sciences and Methodology. Novartis, China Exhibition Room: The Atrium Networking Drinks End of Day One

7 4 th Annual Clinical Asia Congress & 5 th Annual Pharma R&D Asia Congress Day Two 28 th January 2015 Clinical Asia Congress Conference Room 2: New Asia Ballroom Patient Recruitment Strategies: Does One Size Fit all Globally? Can learning from the global operations be translated into effective local strategy The inter-geography variations In patients factors impacting recruitment and retention Perceived differences by investigator s & patients between a generic and innovator product study impacting patient drop-outs Broad guidelines to improve patient retention in clinical trials across geographies CONFIRMED: Akhilesh Sharma, Senior Vice President & Global Head Global Medical Affairs, Dr. Reddy's Laboratories India Solution Provider Presentation For enquiries, please Exhibition Room: The Atrium Morning Coffee & Poster Presentations Poster Presentation Sessions Optimization of the Clinical Trial Conduct CONFIRMED: Jennifer Huang, Executive Director, Head of Global Clinical Trial Operations, Merck Research Laboratories R&D (China) Ltd Clinical Trials in Neurodegenerative Diseases especially Parkinson's Disease CONFIRMED: David Tattersall, Director, Neurodegeneration Parkinson's Disease Group, GSK R&D China Shanghai Developing Clinical Investigators and Sites in Asia & Pacific Region for Global Studies CONFIRMED: Jenny Wei, Head of R&D Information Asia & EM, Innovation Center China, AstraZeneca Global R&D Solution Provider Presentation Lunch - Exhibition Room: The Atrium An Alternative Perspective to Clinical Development: Challenging the Norm with Pharmacometrics CONFIRMED: Jagdev Sidhu, Senior Director Clinical Pharmacology & Pharmacometrics, CSL Limited Australia Opportunities of Bridging Studies in Asia for Global Development CONFIRMED: Patrecia Valone, Senior Director, Development Operations, Takeda Development Center Asia and Takeda Shanghai Development Center Lucitanib, A FGFR, VEGFR, PDGFR Inhibitor in Solid Tumor Introduction of Haihe, A translation/clinical development platform Our collaboration with Servier-the develop of lucitanib - trial in Europe - trial in China CONFIRMED: Lei Jiang, CEO, Shanghai HaiHe Pharmaceutical Co., Ltd Exhibition Room: The Atrium

8 Afternoon Refreshments Practical Considerations For Benefit-Risk Assessments Benefit risk evolves throughout the life-cycle of a drug Signal detection is an ongoing process where no single method will meet all needs and all circumstances All potential signals need to be documented, systematically investigated, and appropriately addressed Pharmaceutical companies cannot effectively monitor the safety of their products without the close cooperation of Health Authorities, healthcare professionals and patients An effective risk management system is the key to maximizing patient benefits while minimizing their risk CONFIRMED: Wei Wang, Associate Director, Safety Surveillance and Risk Management, Pfizer China Research & Development Center, China Managing Pharmacovigilance and Patient Safety Practices for Global Studies, given Ethic and Regulatory Differences CONFIRMED: Ming Ji, Sr. Medical Director, Medical Safety Evaluation, AbbVie End of Conference

2014 Event Sponsors: For more information please contact marketing@oxfodglobalasia.com

2014 Event Sponsors: For more information please contact marketing@oxfodglobalasia.com Oxford Global Conferences are proud to present the 3 rd Annual Clinical Trials & Outsourcing Asia Congress and 4 th Annual Pharma R&D Asia Congress to be held on the 27 th & 28 th February 2014 in Shanghai,

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

Main Conference Agenda

Main Conference Agenda Sponsored by: (Co-located with Bioequivalence: Intersection between Science & Regulatory Conference) Main Conference Agenda Day One Wednesday, November 5 th, 2014 7:30 Registration Opens & Continental

More information

Exhibitors. Key Speakers:

Exhibitors. Key Speakers: Key Speakers: Paul Dolin, Head of Pharmacoepidemiology, Takeda Pharmaceuticals Sandip Chaudhari, Senior Director and Clinical Safety and Risk Management, Pfizer Dr. Katrin Freund, Project Excellence Manager

More information

An Exclusive Interview with Dr Jan-Anders Karlsson

An Exclusive Interview with Dr Jan-Anders Karlsson Dr Jan-Anders Karlsson took over the helm as the CEO of S*BIO from January 2005. He has extensive experience in the pharmaceutical industry, with many proven successes in the drug discovery area. Dr Karlsson

More information

The Hong Kong Association of The Pharmaceutical Industry

The Hong Kong Association of The Pharmaceutical Industry The Hong Kong Association of The Pharmaceutical Industry UNIT A, 20/F., TIMES MEDIA CENTRE, FAX: (852) 2865 6283 WEBSITE: www. hkapi.hk Position Paper on the Pharmacy and Poisons (Amendment) Bill 2014

More information

From IMI to IMI2. Hugh Laverty PROTECT London

From IMI to IMI2. Hugh Laverty PROTECT London From IMI to IMI2 Hugh Laverty 20.02.2015 PROTECT London Innovative Medicines Initiative: Joining forces in the healthcare sector The biggest public/private partnership in Life Science aiming to: Make drug

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30

CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 INTENDED AUDIENCE... 2 METHODOLOGY... 2 ANALYST CREDENTIALS... 2 SCOPE OF REPORT... 2 INFORMATION SOURCES...

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

Clinical Trials Asia Summit 2010

Clinical Trials Asia Summit 2010 19, 20, August 2010, Taj Residency (M.G. Road), Bangalore, India "Improving clinical practice & trial success rates with improved technologies, strategies & alliance management" Key Speakers Include: Akhilesh

More information

BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB

BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB BIOMEDICAL SCIENCES INDUSTRY IN SINGAPORE ROLE OF EDB JAN 2014 1 Singapore s Economic Journey GDP (US$B) 260 240 220 200 180 160 140 120 100 80 60 40 20 0 1960-1969 Labour Intensive 1970 1979 Skill Intensive

More information

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Agenda Section 1 Overview on the Top Ten Pharmaceutical Companies Section

More information

Susmita Gupta, Sr. CDM Project Manager, Endo Pharmaceuticals, USA

Susmita Gupta, Sr. CDM Project Manager, Endo Pharmaceuticals, USA March 4-5 2013, Morristown, NJ, USA www.clinical-trials-events.com/chinausa.html www.clinical-trials-events.com/asiausa.html The 5th China and Asia Clinical Trials Outsourcing Congress Asia has the fastest

More information

Biometrics: Clinical Trials and Beyond

Biometrics: Clinical Trials and Beyond Biometrics: Clinical Trials and Beyond Statistics, Programming, and Data Management in Research, Development, and Regulatory Submissions. For all, Not Just Statisticians! Keynote Presentations Sue-Jane

More information

Strategic Consulting Services

Strategic Consulting Services Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief

More information

Clinical Trials OUTSOURCING & DEVELOPMENT

Clinical Trials OUTSOURCING & DEVELOPMENT Clinical Trials OUTSOURCING & DEVELOPMENT 2-3 rd December Singapore A clinical partnering event for outsourcing and development professionals and service providers in late phase clinical trials DRAFT AGENDA

More information

What Lies Ahead? Trends to Watch: Health Care Product Development in North America

What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the

More information

for the right question

for the right question Real-World & Late Phase Research The right approach for the right question >625 Real-World & Late Phase Programs with >96,000 sites and >810,000 patients in >100 countries since 2011 >180 patient registries

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to

More information

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations

More information

Critical Path Institute

Critical Path Institute Critical Path Institute Accelerating drug development for Alzheimer s Disease through regulatory science Martha A. Brumfield, PhD President and CEO Accelerating the Path to a Healthier World 1 Critical

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality 6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors

More information

IMI2: why, what, how?

IMI2: why, what, how? IMI2: why, what, how? The Right prevention and treatment, to the right patient, at the right time Isabelle Thizon-de Gaulle VP, Strategic initiatives & Scientific relations Sanofi R&D Innovative Medicines

More information

Safety Is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies

Safety Is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies Safety Is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies CLICK HERE to register. PROGRAM COMMITTEE WHO SHOULD ATTEND This program will benefit professionals with

More information

Selling an Idea. Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore

Selling an Idea. Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore Selling an Idea Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore Seminar Format XXXX Know Your Stuff Andy Murray The Beetles Read everything in your field Keep up to date Be dedicated

More information

Sales Force Effectiveness in Pharmaceuticals

Sales Force Effectiveness in Pharmaceuticals Sales Force Effectiveness in Pharmaceuticals Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency GBI Research Report

More information

3rd Annual Patient Recruitment & Retention in Pharma

3rd Annual Patient Recruitment & Retention in Pharma Amsterdam, 23rd - 24th February 2011 3rd Annual Patient Recruitment & Retention in Pharma Who will I meet there? Chairperson Liz Moench President and CEO MediciGlobal Wolfgang Eglmeier Head Clinical Operations

More information

To know more about Pharmacovigilance and Clinical Trials Data Management

To know more about Pharmacovigilance and Clinical Trials Data Management To know more about Pharmacovigilance and Clinical Trials Data Management 1. What is Pharmacovigilance? Pharmacovigilance (PV) is the pharmacological science related to the detection, assessment, understanding

More information

Accelerating Drug & Clinical Trial Approvals in China & East Asia

Accelerating Drug & Clinical Trial Approvals in China & East Asia 25 28 March 2014 The Westin Beijing Chaoyang, Accelerating Drug & Clinical Trial Approvals in & East Asia What s New in 2014? Key Regulatory Update from the National Institute for Food & Drug Control,

More information

2014 & 13 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit

2014 & 13 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit 2014 & 13 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit Addressing the most critical issues facing China s pharma & life science sector 10 th & 11 th April, 2014 Shanghai China

More information

BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES

BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES HEALTHCARE BIOTECHNOLOGY In Spain the development of ageing medicine presents an excellent business opportunity because the population

More information

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines The R&D Process: Long, Complex, and Costly Average cost of R&D is $1.2 Billion The Current Challenge

More information

Quality by Design Concept

Quality by Design Concept 3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,

More information

The Role of Regional Medical Advisor (RMA)-Field Medical. Dr. Aju Abraham Varghese Pfizer India. Feb 22 nd 2014

The Role of Regional Medical Advisor (RMA)-Field Medical. Dr. Aju Abraham Varghese Pfizer India. Feb 22 nd 2014 The Role of Regional Medical Advisor (RMA)-Field Medical Dr. Aju Abraham Varghese Pfizer India Feb 22 nd 2014 Disclaimer The opinions expressed in this presentation are solely those of the presenter and

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

CLINICAL DEVELOPMENT OPTIMIZATION

CLINICAL DEVELOPMENT OPTIMIZATION PAREXEL CLINICAL RESEARCH SERVICES CLINICAL DEVELOPMENT OPTIMIZATION Enhancing the clinical development process to achieve optimal results ADVANCED TECHNOLOGY COMBINED WITH INTELLIGENT THINKING CAN HELP

More information

Unlock Your Global Business Potential: Supporting Life Sciences in the UK

Unlock Your Global Business Potential: Supporting Life Sciences in the UK Unlock Your Global Business Potential: Supporting Life Sciences in the UK Dr Mark Treherne, Chief Executive, Life Science Investment Organisation Health Research Authority 31 st March, 2014 THE UK HAS

More information

Pharmaceutical Quality & Clinical Research Quality: The Interaction

Pharmaceutical Quality & Clinical Research Quality: The Interaction 4 th Jerusalem Conference: Quality by Design (QbD)) & Pharma Sciences, May 20-22, 2014 The Edmund Safra Campus, The Hebrew University of Jerusalem Pharmaceutical Quality & Clinical Research Quality: The

More information

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical

More information

Next Generation Sequencing Informatics Markets

Next Generation Sequencing Informatics Markets Next Generation Sequencing Informatics Markets Greg Caressi SVP Healthcare & Life Sciences November, 2014 Personalization, Communication, Decentralization, Collaboration From... One Size Fits All APPROACH...To

More information

Emerging Early Clinical Research Capabilities in Asia-Pacific. Dr. Chew Lan CHONG Executive Director, Medical Research Feb 2015

Emerging Early Clinical Research Capabilities in Asia-Pacific. Dr. Chew Lan CHONG Executive Director, Medical Research Feb 2015 Emerging Early Clinical Research Capabilities in Asia-Pacific Dr. Chew Lan CHONG Executive Director, Medical Research Feb 2015 Questions What is driving the interest in performing early clinical research

More information

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Paulina Ramirez: Birmingham Business School IRIMA Workshop on the Internationalisation

More information

Public Policy Statement: Clinical Trial Ethics

Public Policy Statement: Clinical Trial Ethics Public Policy Statement: Clinical Trial Ethics Purpose As a global healthcare company, Merck's role is first and foremost to discover, develop and provide innovative products and services that save and

More information

Career Pathways: Breaking into the Business of Regulatory Affairs & Biotechnology. Wednesday, April 20, 2016

Career Pathways: Breaking into the Business of Regulatory Affairs & Biotechnology. Wednesday, April 20, 2016 Career Pathways: Breaking into the Business of Regulatory Affairs & Biotechnology Wednesday, April 20, 2016 Agenda 6:00 6:15 Welcome Dave Dimas 6:15 6:40 Overview of Biotech Careers - Miles McLennan 6:40

More information

KEEPING CLINICAL TRIALS IN AUSTRALIA

KEEPING CLINICAL TRIALS IN AUSTRALIA OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought

More information

2015 / 2016 Awards Criteria and Submission Information

2015 / 2016 Awards Criteria and Submission Information 9 th Annual ViE Awards 2015 / 2016 Awards Criteria and Submission Information In association with: Dear colleague, The Vaccine Industry Excellence (ViE) Awards have been created to honor and generate recognition

More information

Spring 2013. From Our CEO. Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai

Spring 2013. From Our CEO. Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai From Our CEO Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai Featured Story WuXi and PRA Form Joint Venture to Offer Clinical Research Services

More information

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials

More information

Key Findings. Use this report to... The Top 10 Contract Research Organizations

Key Findings. Use this report to... The Top 10 Contract Research Organizations Key Findings The global CRO industry valued $18bn in 2008, an increase of 14% over 2007. The CRO market will grow at an annual rate of 14% over the 2009 13 period. Quintiles leads the global CRO market

More information

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Transparency Market Research Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample Published Date:

More information

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge

More information

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be

More information

LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO. @LSQld

LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO. @LSQld LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO @LSQld LEADING DESTINATION FOR CLINICAL RESEARCH INVESTORS IN QLD INCLUDE: LIFE SCIENCES IN QLD ~300 companies in life sciences ~$5B invested by

More information

FINAL PROGRAM APEC LSIF. First ICH Quality Guidelines Q8, Q9, Q10 Seminar. Opportunities and Challenges Related to Implementation

FINAL PROGRAM APEC LSIF. First ICH Quality Guidelines Q8, Q9, Q10 Seminar. Opportunities and Challenges Related to Implementation PartDRAFT: of September APEC3Life Sciences Innovation Forum Projects FINAL PROGRAM APEC LSIF First ICH Quality Guidelines Q8, Q9, Q10 Seminar Opportunities and Challenges Related to Implementation September

More information

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;

More information

Safety Risk Management Company Perspective

Safety Risk Management Company Perspective Safety Risk Management Company Perspective Akihisa Harada, MD, Ph.D VP, Development Japan Pfizer Japan Inc. R&D Head Club Agenda REMS in FDAAA Safety Risk Management throughout a Drug s Lifecycle Risk

More information

In the largest and perhaps the most ambitious collaborative

In the largest and perhaps the most ambitious collaborative FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated

More information

Location for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014

Location for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Location for Trials- Global Considerations A Pharma Perspective Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Why Choose Australia for Clinical Trials? What is he saying

More information

Safety Science Leader, LEAD

Safety Science Leader, LEAD Date: 07/06/16 Safety Science Leader, LEAD Job ID: 00448399 Job Function Drug Safety Location United States - California South San Francisco Company/Division Full-time Schedule Full-time Job type Regular

More information

Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure

Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure Policy Issues in the Economics and Financing of Medical Technology in the Asia-Pacific Region Dr KAI HONG PHUA Joint Professor Yong Loo Lin School of Medicine and Lee Kuan Yew School of Public Policy National

More information

In-depth analysis of the report is based on propriety databases, primary and secondary research and inhouse analysis by a team of experts.

In-depth analysis of the report is based on propriety databases, primary and secondary research and inhouse analysis by a team of experts. Brochure More information from http://www.researchandmarkets.com/reports/1882193/ Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising

More information

DIA 2016. 52 ND Annual Meeting. Exhibitor Prospectus

DIA 2016. 52 ND Annual Meeting. Exhibitor Prospectus DIA 2016 52 ND Annual Meeting MEETING DATES: JUNE 26-30, 2016 EXHIBIT DATES: JUNE 27-29, 2016 Pennsylvania Convention Center Philadelphia, PA Exhibitor Prospectus Join the who s who in the life sciences

More information

Clinical trials in haemophilia

Clinical trials in haemophilia Clinical trials in haemophilia Dr. Paul Giangrande Oxford Haemophilia and Thrombosis Centre & Nuffield Department of Clinical Medicine University of Oxford paul.giangrande@ndm.ox.ac.uk Why do clinical

More information

PROVENTA INTERNATIONAL INNOVATION. Strategies for Transforming Safety, Regulatory, and Benefit-Risk Management of Established Products

PROVENTA INTERNATIONAL INNOVATION. Strategies for Transforming Safety, Regulatory, and Benefit-Risk Management of Established Products INNOVATION SPOTLIGHT SESSION Strategies for Transforming Safety, Regulatory, and Benefit-Risk Management of Established Products WEDNESDAY 4TH NOVEMBER 2015 Hyatt Regency, Princeton, NJ PROVENTA INTERNATIONAL

More information

Biomedical Accelerator Fund. Office of Technology Development Harvard University

Biomedical Accelerator Fund. Office of Technology Development Harvard University Biomedical Accelerator Fund Office of Technology Development Harvard University Curtis Keith, Chief Scientific Officer May 21, 2012 Mission of Harvard s Office 2 Organizational Structure of Harvard OTD

More information

BIOCLINICA, INC. TO DEMONSTRATE TECHNOLOGY-ENHANCED CAPABILITIES AT UPCOMING GLOBAL INDUSTRY EVENTS

BIOCLINICA, INC. TO DEMONSTRATE TECHNOLOGY-ENHANCED CAPABILITIES AT UPCOMING GLOBAL INDUSTRY EVENTS Company Contact - Jim Dorsey BioClinica, Inc. 267-757-3040 Trade Media Morgan Dub Karpo Diccicco Battista Communications 484-342-3600 FOR IMMEDIATE RELEASE BIOCLINICA, INC. TO DEMONSTRATE TECHNOLOGY-ENHANCED

More information

Biosimilars 20/20. The Future is at Hand

Biosimilars 20/20. The Future is at Hand Welcome to Biosimilars 20/20, presented by the Specialty Pharma Education Center (SPEC) in partnership with the Specialty Pharma Journal (SPJ). Please note that this is a preliminary agenda that is subject

More information

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013 Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory

More information

APAC CRO Market A deep dive into the trends transforming APAC CRO industry. P86A-52 June 2015

APAC CRO Market A deep dive into the trends transforming APAC CRO industry. P86A-52 June 2015 APAC CRO Market A deep dive into the trends transforming APAC CRO industry June 2015 Table of Contents Section Slide Numbers Executive Summary 10 Key Findings 11 Total CRO Market Size By Stages of Clinical

More information

Harmonized Core Competencies in Clinical Research: evolutions and next steps for meeting the challenge

Harmonized Core Competencies in Clinical Research: evolutions and next steps for meeting the challenge Harmonized Core Competencies in Clinical Research: evolutions and next steps for meeting the challenge Master of Applied Clinical and Preclinical Research macpr.osu.edu Consortium of Academic Programs

More information

SPEAKER BIOGRAPHICAL INFORMATION

SPEAKER BIOGRAPHICAL INFORMATION SPEAKER BIOGRAPHICAL INFORMATION Madeleine R. Valera MD, MScIH (Heidelberg) Dr. Valera is a senior health care service professional with over 20 years of professional expertise in Health Financing and

More information

Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies

Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial

More information

The Future of R&D Outsourcing

The Future of R&D Outsourcing OUTSOURCING The Future of R&D Outsourcing Investigating development hurdles, key challenges & strategies to optimize CRO relationships By Alison Sahoo Alison Sahoo Alison Sahoo is a pharmaceutical industry

More information

ORPHAN DRUG. ORPHAN DRUG & RARE DISEASE DEVELOPMENT: Understanding the U.S. and European Regulatory Landscape & RARE DISEASE DEVELOPMENT

ORPHAN DRUG. ORPHAN DRUG & RARE DISEASE DEVELOPMENT: Understanding the U.S. and European Regulatory Landscape & RARE DISEASE DEVELOPMENT : Abstract Today, more than ever, researchers are focused on providing care for the approximately 7,000 rare diseases that may have been overlooked in the past due to the challenges of conducting clinical

More information

Novartis: transforming our company for the future market

Novartis: transforming our company for the future market Novartis: transforming our company for the future market Joe Jimenez CEO Novartis JP Morgan Conference San Francisco January 12, 2015 Disclaimer This presentation contains forward-looking statements that

More information

Later-Stage Development: Ensuring Compliance During. for a Competitive Advantage Webinar Series

Later-Stage Development: Ensuring Compliance During. for a Competitive Advantage Webinar Series Part II: Later-Stage Development: Ensuring Compliance During Clinical i l Trials Process Driven Compliance for a Competitive Advantage Webinar Series 29 September 2010 Process Driven Compliance Webinar

More information

The new strategic approach to better medicines in IMI2 Example Diabetes Mellitus

The new strategic approach to better medicines in IMI2 Example Diabetes Mellitus The new strategic approach to better medicines in IMI2 Example Diabetes Mellitus Bernd Stowasser, PhD, MS, Associate Vice President, Head of European Public Private Partnerships Office Sanofi R&D Strategy,

More information

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final Draft Final EFPIA Position Paper on REACH Author: EFPIA Date: October 2015 Version: Final Position Paper Executive Summary An increasing number of substances used in the pharmaceutical manufacturing process

More information

- The need for sales force effectiveness for pharmaceutical companies and the factors that affect it.

- The need for sales force effectiveness for pharmaceutical companies and the factors that affect it. Brochure More information from http://www.researchandmarkets.com/reports/2204703/ Sales Force Effectiveness in Pharmaceuticals - Targeted Sales Models such as Enhanced Key Account Management (KAM) and

More information

Trends in Innovation in Middle Income Countries: The Case of Biotechnology

Trends in Innovation in Middle Income Countries: The Case of Biotechnology Trends in Innovation in Middle Income Countries: The Case of Biotechnology Joseph Damond, Senior Vice President, International Affairs, Biotechnology Industry Organization INNOVATION AND ACCESS TO MEDICAL

More information

Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015

Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute

More information

A PROVEN APPROACH to ACCELERATED CLINICAL DEVELOPMENT

A PROVEN APPROACH to ACCELERATED CLINICAL DEVELOPMENT Accelovance 2275 Research Boulevard, Suite 700 Rockville, MD 20850, United States Phone: +1.240.238.4900 Fax: +1.240.238.4901 Internet: www.accelovance.com email: gsmith@accelovance.com Contact Person:

More information

Supplier Diversity in Pharmaceutical R&D

Supplier Diversity in Pharmaceutical R&D WHITEPAPER March 2015 www.beroeinc.com Supplier Diversity in Pharmaceutical R&D Author Meenakshi L 1 Copyright Beroe Inc, 2015. All Rights Reserved Abstract / Business Case Procurement decisions are no

More information

Investment summit supports Australian biotech industry to attract investment and grow

Investment summit supports Australian biotech industry to attract investment and grow Investment summit supports Australian biotech industry to attract investment and grow During 2014, more than $500 million in investment was raised for Australian biotech. A Scientific American survey of

More information

Committed to innovation and growth

Committed to innovation and growth Committed to innovation and growth Alan Hippe, CFO Roche Group London, September 2012 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by

More information

Future In Life Sciences

Future In Life Sciences Future In Life Sciences Event Series Sponsorship Overview About the Partnership Propel Careers, MassBio, and the MassBioEd joined together in 2011 to organize a series of networking and panel events focused

More information

JOHN REID PhD, MBA. (302) 544-1743 entrepidbd@gmail.com http://www.linkedin.com/in/jdreid1

JOHN REID PhD, MBA. (302) 544-1743 entrepidbd@gmail.com http://www.linkedin.com/in/jdreid1 JOHN REID PhD, MBA (302) 544-1743 entrepidbd@gmail.com http://www.linkedin.com/in/jdreid1 PROFILE Senior-level business development and licensing executive with a well-honed ability to translate scientific

More information

ROOT CAUSE ANALYSIS. Prevent Non-Compliance and Achieve Successful Root Cause Analyses and CAPA Systems Implementation from Clinical to Post-Market

ROOT CAUSE ANALYSIS. Prevent Non-Compliance and Achieve Successful Root Cause Analyses and CAPA Systems Implementation from Clinical to Post-Market 5th SIGNAL DETECTION, ROOT CAUSE ANALYSIS & January 22-23, 2015 Key Bridge Marriott Arlington, VA Prevent Non-Compliance and Achieve Successful Root Cause Analyses and CAPA Systems Implementation from

More information

Challenges in Developing Therapeutics in Partially Responsive and Treatment Resistant Depression Where do we go from here?

Challenges in Developing Therapeutics in Partially Responsive and Treatment Resistant Depression Where do we go from here? Challenges in Developing Therapeutics in Partially Responsive and Treatment Resistant Depression Where do we go from here? Heddie Martynowicz, MS Senior Director, Global Regulatory Affairs Janssen R &

More information

A leader in the development and application of information technology to prevent and treat disease.

A leader in the development and application of information technology to prevent and treat disease. A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today

More information

New Opportunities in IMI2. Hugh Laverty ECSEL Consortium Building Event Brussels

New Opportunities in IMI2. Hugh Laverty ECSEL Consortium Building Event Brussels New Opportunities in IMI2 Hugh Laverty 14.04.2015 ECSEL Consortium Building Event Brussels Innovative Medicines Initiative: Joining forces in the healthcare sector The biggest public/private partnership

More information

ACC San Diego Chapter

ACC San Diego Chapter ACC San Diego Chapter Biomedical and Technology Collaborations with Chinese Companies: Legal and Cultural Challenges October 2012 DLA Piper Overview Our Firm 4,200 lawyers in 77 offices and 33 countries

More information

Regulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG

Regulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG Regulatory Affairs Graduate Postgraduate Program Novartis Pharma AG Novartis Animal Health AG The Regulatory Affairs (RA) Graduate Program is an opportunity to discover the global functions of Drug Regulatory

More information

BIG DATA BREATHES LIFE INTO NEXT-GEN PHARMA R&D

BIG DATA BREATHES LIFE INTO NEXT-GEN PHARMA R&D www.wipro.com BIG DATA BREATHES LIFE INTO NEXT-GEN PHARMA R&D Dr.Sarika Vanarse Principal Consultant Pharma R&D, Industry Solutions Group Table of Contents 03... Abstract 03... Introduction 05... Preparing

More information

POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS News Release POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS FRAME Study Met All Primary Endpoints by Reducing the Incidence of New Vertebral Fracture

More information